CompletedNot Applicable

Assessment of Wall Thickness in Hypertrophic Cardiomyopathy

United States110 participantsStarted 2014-10

Plain-language summary

Assessment of wall thickness in hypertrophic cardiomyopathy (HCM) is of diagnostic and prognostic importance given its known association with sudden cardiac death. However, data regarding comparison of imaging modalities for this key measurement is lacking. This study seeks to compare assessment of maximum wall thickness between clinically indicated echocardiography (with and without contrast) and clinically indicated cardiac magnetic resonance imaging.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Clinically and echocardiographically defined hypertrophic cardiomyopathy.
✓. Clinically indicated transthoracic echocardiography as part of the medical evaluation.
✓. No contradiction to administration of ultrasonic echocardiography contrast.
✓. Planned clinically indicated cardiac magnetic resonance imaging as part of medical evaluation.
✓. No contraindication to cardiac magnetic resonance imaging (such as cochlear implants, central nervous system aneurysm clips and other implanted medical devices).
✓. Age 18 years and older

What they're measuring

Left Ventricular Wall Thickness

Timeframe: approximately 1 week after enrollment

Trial details

NCT IDNCT02234336

SponsorMayo Clinic

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2017-07-25

View on ClinicalTrials.gov More Hypertrophic Cardiomyopathy trials